The Nippon India Nifty Pharma ETF delivered a 6.8% return over the last month, outperforming other index-based funds. This strong performance follows a consistent trend of beating its benchmark over one-year and three-year periods. Investors should note that ETFs are designed to mirror specific market indices, making tracking difference and liquidity essential factors for evaluation.
Detailed Coverage
The Nippon India Nifty Pharma ETF has recently emerged as a top performer in the index exchange-traded fund category, recording a 6.8% return over the one-month period ending July 21, 2026. This data, compiled by ACE MF for funds with assets under management above ₹1,500 crore, places it ahead of other prominent sectoral and strategy-based ETFs.
Comparing Performance and Strategy
While the pharma-focused ETF saw notable gains, other major index funds experienced varied results. For instance, the Nippon India ETF Nifty IT, which manages the largest corpus among the top five funds at ₹3,532.7 crore, saw a decline of 8.0% during the same month. Another peer, the ICICI Prudential Nifty Alpha Low-Volatility 30 ETF, recorded a more modest return of 3.2%. These differences highlight how sector-specific movements can lead to varied outcomes for passive funds that track specific indices.
Historical Outperformance Against Benchmarks
The recent one-month performance is part of a longer-term trend for the Nippon India Nifty Pharma ETF. The fund has shown a consistent ability to outperform its underlying Nifty Pharma index. Over a one-year period, the ETF delivered a 16.4% return, while its benchmark index registered a return of -2.5%, marking a difference of 18.9 percentage points. This pattern extends to the six-month horizon, where the fund returned 21.3%, and the three-year period, where it posted a compound annual growth rate of 22.8%.
What Investors Should Monitor
For those looking at index ETFs, it is important to understand that these funds are designed to replicate the performance of a specific index rather than pick individual winning stocks. When assessing an ETF's value, investors may monitor the tracking difference—which is the variance between the fund's returns and the index it follows—as well as the tracking error. Liquidity is another practical factor, as it determines how easily an investor can buy or sell units on the exchange at prices close to the fund's actual value. Since sectoral ETFs are sensitive to the health of the pharmaceutical industry, future returns will likely depend on earnings growth, export demand, and regulatory updates within the domestic and global pharma space.